Stock CLGN COLLPLANT HOLDINGS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Collplant Holdings Ltd Stock TEL AVIV STOCK EXCHANGE

Equities

CLGN

IL0004960188

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 		5-day change 1st Jan Change
- ILa -.--% Intraday chart for Collplant Holdings Ltd -14.91% -.--%
Apr. 04 CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 02 CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants CI

Financials

Sales 2024 * 10.53M 2.77M 1.05B Sales 2025 * 53.98M 14.21M 5.4B Capitalization 228M 59.95M 22.78B
Net income 2024 * -60M -15.79M -6B Net income 2025 * -24M -6.32M -2.4B EV / Sales 2024 * 21.6 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 4.22 x
P/E ratio 2024 *
-3.69 x
P/E ratio 2025 *
-9.19 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 67.13%
More Fundamentals * Assessed data

Chart Collplant Holdings Ltd

Dynamic Chart

Latest news about Collplant Holdings Ltd

CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants CI
Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $43,000 MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
CollPlant Biotechnologies Issued US Patent for Photocurable Dermal Filler MT
Wall Street Set to Open Slightly Higher; Weekly Jobless Claims Fall to Near Historic Lows MT
Top Premarket Decliners MT
Earnings Flash (CLGN) COLLPLANT Reports Q2 Revenue $10.2M MT
Earnings Flash (CLGN) COLLPLANT Posts Q2 EPS $0.52 MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
CollPlant to Receive $10 Million Milestone Payment From AbbVie Under Dermal Filler Product Deal; Shares Rise MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Stratasys, CollPlant Biotechnologies to Bio-Fabricate Human Tissues, Organs MT
Stratasys Ltd. and Collplant Biotechnologies Ltd. to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs CI
HC Wainwright Adjusts Price Target on CollPlant Holdings to $11 From $26, Maintains Buy Rating MT
More news

Analyst Recommendations on Collplant Holdings Ltd

HC Wainwright Adjusts Price Target on CollPlant Holdings to $11 From $26, Maintains Buy Rating MT
COLLPLANT BIOTECHNOLOGIES : HC Wainwright Adjusts Price Target on CollPlant Holdings to $26 From $13, Keeps Buy Rating MT
More recommendations

Press releases Collplant Holdings Ltd

COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION PR
CollPlant Issues Letter to Shareholders PR
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants PR
More press releases

Managers and Directors - Collplant Holdings Ltd

Managers TitleAgeSince
Yehiel Tal CEO
 Chief Executive Officer 71 09-12-31
Oded Shoseyov FOU
 Founder 67 04-05-31
Eran Rotem DFI
 Director of Finance/CFO 56 11-12-31
Members of the board TitleAgeSince
Avri Havron BRD
 Director/Board Member 75 16-04-30
Hugh Evans BRD
 Director/Board Member 57 21-03-28
Elan Penn BRD
 Director/Board Member 72 17-12-31
More insiders

Company Profile

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Sector
Biotechnology & Medical Research
Calendar
2024-05-22 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Collplant Holdings Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.24 USD
Average target price
11 USD
Spread / Average Target
+109.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Medical Devices

1st Jan change Capi.
MIMEDX GROUP, INC. Stock MiMedx Group, Inc.
-27.82% 916M
NIBEC CO., LTD. Stock NIBEC Co., Ltd.
-22.12% 125M
KIM FOREST ENTERPRISE CO., LTD. Stock Kim Forest Enterprise Co., Ltd.
+1.90% 57.56M
BONUS BIOGROUP LTD. Stock Bonus BioGroup Ltd.
-2.40% 51.27M
Bio Medical Devices
  1. Stock Market
  2. Equities
  3. CLGN Stock
  4. CLGN Stock